Diagnosis and treatment of autoimmune acquired coagulation factor V deficiency

Key Points

• This research aims to address the diagnosis and management of autoimmune acquired coagulation factor V deficiency (AiF5D).
• Diagnosed through extended coagulation times and reduced factor V activity.
• Involves confirming the presence of inhibitors and using immunological assays.
• Differentiates from lupus anticoagulant through laboratory testing.
• Approximately 15% mortality rate associated with AiF5D.
• Major causes of death include severe hemorrhage, infections, and thrombosis.
• Early diagnosis and therapies are crucial for improving outcomes.